NCT07868211Not yet recruiting
Effect of Dietary Fiber Supplementation on Systemic Inflammation and Clinical Parameters in COPD
Efeito Da Suplementação Dietética De Fibras Sobre Inflamação Sistêmica E Parâmetros Clínicos Na DPOC: Ensaio Clínico Randomizado, Duplo-Cego E Controlado Por Placebo
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent respiratory symptoms and systemic inflammation. Dietary fiber intake has been associated with beneficial effects on gut microbiota composition and systemic inflammatory markers. This study aims to evaluate the effects of dietary fiber supplementation on systemic inflammation and clinical parameters in patients with COPD through a randomized, double-blind, placebo-controlled trial.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 30 Sept 2026
- Start date
- Nov 2026
- Primary completion date
- Apr 2027
- Lead sponsor
- Júnea Regina Pires Drews
- Diseases
- COPD
- NCT number
- NCT07868211
What you commit to
- Study type: Interventional
- Planned participants: 100
- From Nov 2026 to the primary completion date, Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Lung transplant recipients
- Diagnosed COPD exacerbation (ECOPD) within the 3 months prior to study start
- Major changes in COPD maintenance therapy within 3 months prior to screening
- Use of a short course of oral corticosteroids within 4 weeks prior to Day 1 of the study
Other illness
- Interstitial lung disease
- Severe comorbidities impacting outcomes (severe pancreatic, hepatic, renal, or cardiac disease; inflammatory bowel disease; active neoplasm with prognostic impact; human immunodeficiency virus/AIDS; active pulmonary tuberculosis; multiple sclerosis)
- Any other condition identified during the screening visit by the investigator or nurse that could interfere with the study or patient safety
- Recent acute respiratory infection
Other
- End-stage COPD (GOLD stage 4)
- Primary diagnosis of asthma
- Unwillingness or inability to comply with study procedures (e.g., inability to record dietary intake, attend visits, or manage oral supplementation)
- Pregnant, breastfeeding, or planning to become pregnant
- Change in smoking habits within the last 6 months
- Requirement for other nutritional supplements or parenteral nutrition
- Daily dietary fiber intake exceeding 28 grams for women or 34 grams for men
Who the study is looking for
- Inclusion Criteria:
- Diagnosis of COPD with no exacerbation episodes in the last 3 months
- Aged 18 to 75 years
- Patient at the Interstitial Lung Diseases Outpatient Clinic of Hospital das Clínicas da UFMG
- Ability to perform spirometry
- Ability to perform the 6-minute walk test (6MWT)
- Willingness to participate in the study and signed Informed Consent Form (ICF)
- Ability to read and write
- Daily dietary fiber intake between 10 and 20 grams
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital das Clínicas da UFMG - Ambulatório de Doenças Pulmonares Intersticiais Coordinator of this site? Confirm its status | Belo Horizonte | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.